149 related articles for article (PubMed ID: 28819904)
1. Somatic mutations of calreticulin in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable.
Zhang X; Pan J
Ann Hematol; 2017 Nov; 96(11):1949-1951. PubMed ID: 28819904
[No Abstract] [Full Text] [Related]
2. Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Rumi E; Cazzola M
Haematologica; 2014 Nov; 99(11):1650-2. PubMed ID: 25420280
[No Abstract] [Full Text] [Related]
3. The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms.
Meggendorfer M; Jeromin S; Haferlach C; Kern W; Haferlach T
Haematologica; 2018 May; 103(5):e192-e195. PubMed ID: 29700173
[No Abstract] [Full Text] [Related]
4. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.
Li Y; Beck RC; Moore EM
Am J Clin Pathol; 2021 Sep; 156(4):634-643. PubMed ID: 33877292
[TBL] [Abstract][Full Text] [Related]
5. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
6. Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted.
Mangaonkar AA; Swoboda DM; Lasho TL; Finke C; Ketterling RP; Reichard KK; Padron E; Talati C; Patnaik MM
Leukemia; 2021 Nov; 35(11):3329-3333. PubMed ID: 33931725
[No Abstract] [Full Text] [Related]
7. Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.
Ali H; Puccio I; Akarca AU; Bob R; Pomplun S; Keong Wong W; Gupta R; Sekhar M; Lambert J; Al-Masri H; Stein H; Marafioti T
Int J Exp Pathol; 2021 Feb; 102(1):45-50. PubMed ID: 32929772
[TBL] [Abstract][Full Text] [Related]
8. MDS/MPN-U with persistent monocytosis, del(20q), and CALR mutation, the great masquerader.
Xu Z; Berry BR
Blood; 2020 May; 135(19):1718. PubMed ID: 32379880
[No Abstract] [Full Text] [Related]
9. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
[TBL] [Abstract][Full Text] [Related]
10. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.
Bose P; Nazha A; Komrokji RS; Patel KP; Pierce SA; Al-Ali N; Sochacki A; Shaver A; Ma W; Su X; Daver NG; DiNardo CD; Garcia-Manero G; Loghavi S; Bueso-Ramos C; Kantarjian HM; Sekeres MA; Savona MR; Maciejewski JP; Verstovsek S
Blood; 2018 Nov; 132(19):2100-2103. PubMed ID: 30242087
[No Abstract] [Full Text] [Related]
11. Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Zamora L; Xandri M; Garcia O; Marcé S; Xicoy B; Granada I; Navarro JT; Millá F
Am J Clin Pathol; 2012 Apr; 137(4):677-8. PubMed ID: 22431549
[No Abstract] [Full Text] [Related]
12. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.
Score J; Hidalgo-Curtis C; Jones AV; Winkelmann N; Skinner A; Ward D; Zoi K; Ernst T; Stegelmann F; Döhner K; Chase A; Cross NC
Blood; 2012 Feb; 119(5):1208-13. PubMed ID: 22053108
[TBL] [Abstract][Full Text] [Related]
14. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
15. Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects.
Harada H
Int J Hematol; 2017 Jun; 105(6):709-710. PubMed ID: 28447249
[No Abstract] [Full Text] [Related]
16. Genomics of myelodysplastic/myeloproliferative neoplasm.
Patwardhan PP; Aarabi M; Aggarwal N
Semin Diagn Pathol; 2023 May; 40(3):195-201. PubMed ID: 37105794
[TBL] [Abstract][Full Text] [Related]
17. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
Cazzola M; Kralovics R
Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms.
Lundberg P; Nienhold R; Ambrosetti A; Cervantes F; Pérez-Encinas MM; Skoda RC
Blood; 2014 Apr; 123(17):2744-5. PubMed ID: 24764562
[No Abstract] [Full Text] [Related]
19. [A case report of RARS-T with SF3B1 and CALR mutations].
Ge H; Zhou Z; Chu H
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):347. PubMed ID: 27094003
[No Abstract] [Full Text] [Related]
20. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
